Breaking News, Trials & Filings

Merck Serono, BioMarin Submit MAA

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck Serono, a division of Merck KGaA, has submitted an MAA to the EMEA for sapropterin dihydrochloride (Kuvan in the U.S.) as an oral treatment for patients suffering from significant hyperphenylalaninemia (HPA) due to phenylketonuria (PKU) or tetrahydrobiopterin (BH4) deficiency. The compound is being developed in collaboration with BioMarin Pharma. Acceptance of the MAA filing triggered a $15 million milestone payment to BioMarin. Sapropterin has received orphan medicinal product designat...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters